Literature DB >> 28680132

Visual loss and other cranial ischaemic complications in giant cell arteritis.

Alessandra Soriano1,2, Francesco Muratore1,3, Nicolò Pipitone1, Luigi Boiardi1, Luca Cimino4, Carlo Salvarani1,3.   

Abstract

Giant cell arteritis (GCA) is the most common form of vasculitis in individuals aged 50 years and over. GCA typically affects large and medium-sized arteries, with a predilection for the extracranial branches of the carotid artery. Patients with GCA usually present with symptoms and signs that are directly related to the artery that is affected, with or without constitutional manifestations. The most dreaded complication of GCA is visual loss, which affects about one in six patients and is typically caused by arteritis of the ophthalmic branches of the internal carotid artery. Before the advent of glucocorticoid treatment, the prevalence of visual complications was high. Increasing awareness by physicians of the symptoms of GCA and advances in diagnostic techniques over the past twenty years have also contributed to a substantial decline in the frequency of permanent visual loss. Ischaemic brain lesions are less common than visual lesions, and mostly result from vasculitis of the extradural vertebral or carotid arteries. In the case of both the eye and the brain, ischaemic damage is thought to result from arterial stenosis or occlusion that occurs secondary to the inflammatory process. The inflammatory response at the onset of arteritis, its role as a predictor of complications and the role of traditional cardiovascular risk factors have been extensively investigated in the past decade. In this Review, the epidemiology, risk factors, clinical presentation and current therapeutic approach of GCA-related ischaemic events are discussed, with a particular emphasis on visual loss.

Entities:  

Mesh:

Year:  2017        PMID: 28680132     DOI: 10.1038/nrrheum.2017.98

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  85 in total

1.  Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study.

Authors:  G G Hunder; S G Sheps; G L Allen; J W Joyce
Journal:  Ann Intern Med       Date:  1975-05       Impact factor: 25.391

2.  Temporal arteritis; a generalized vascular disease.

Authors:  W T COOKE; P C P CLOAKE
Journal:  Q J Med       Date:  1946-01

3.  A functional variant of vascular endothelial growth factor is associated with severe ischemic complications in giant cell arteritis.

Authors:  Blanca Rueda; Miguel A Lopez-Nevot; Maria J Lopez-Diaz; Carlos Garcia-Porrua; Javier Martín; Miguel A Gonzalez-Gay
Journal:  J Rheumatol       Date:  2005-09       Impact factor: 4.666

4.  Visual performance in giant cell arteritis (temporal arteritis) after 1 year of therapy.

Authors:  M J Kupersmith; R Langer; H Mitnick; R Spiera; H Spiera; M Richmond; S Paget
Journal:  Br J Ophthalmol       Date:  1999-07       Impact factor: 4.638

5.  Antiplatelet and anticoagulant therapy in patients with giant cell arteritis.

Authors:  Michael S Lee; Scott D Smith; Anat Galor; Gary S Hoffman
Journal:  Arthritis Rheum       Date:  2006-10

6.  Characteristics of cerebrovascular accidents at time of diagnosis in a series of 98 patients with giant cell arteritis.

Authors:  Thierry Zenone; Marie Puget
Journal:  Rheumatol Int       Date:  2013-07-20       Impact factor: 2.631

7.  Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism.

Authors:  José Hernández-Rodríguez; Marta Segarra; Carme Vilardell; Montse Sánchez; Ana García-Martínez; María-José Esteban; Josep M Grau; Alvaro Urbano-Márquez; Dolors Colomer; Hynda K Kleinman; Maria C Cid
Journal:  Circulation       Date:  2003-05-12       Impact factor: 29.690

8.  Evaluating the Incidence of Arteritic Ischemic Optic Neuropathy and Other Causes of Vision Loss from Giant Cell Arteritis.

Authors:  John J Chen; Jacqueline A Leavitt; Chengbo Fang; Cynthia S Crowson; Eric L Matteson; Kenneth J Warrington
Journal:  Ophthalmology       Date:  2016-06-11       Impact factor: 12.079

9.  PlA1/A2 polymorphism of the platelet glycoprotein receptor IIIA and risk of cranial ischemic complications in giant cell arteritis.

Authors:  Carlo Salvarani; Bruno Casali; Enrico Farnetti; Nicolò Pipitone; Debora Formisano; Davide Nicoli; PierLuigi Macchioni; Luca Cimino; GianLuigi Bajocchi; Maria Grazia Catanoso; Giovanna Restuccia; Alessandra Ghinoi; Luigi Boiardi
Journal:  Arthritis Rheum       Date:  2007-10

Review 10.  Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature.

Authors:  Sohan Singh Hayreh; Bridget Zimmerman; Randy H Kardon
Journal:  Acta Ophthalmol Scand       Date:  2002-08
View more
  30 in total

Review 1.  Monckeberg's Medial Sclerosis as a Cause for Headache and Facial Pain.

Authors:  Davis C Thomas; Prisly Thomas; Anilkumar Sivan; Priyanka Unnam; Ahana Ajayakumar; Sanjana Santhosh Kumar; Priyanka Kodaganallur Pitchumani; Mahnaz Fatahzadeh; Nida-E-Haque Mahmud
Journal:  Curr Pain Headache Rep       Date:  2021-06-04

2.  MMP (Matrix Metalloprotease)-9-Producing Monocytes Enable T Cells to Invade the Vessel Wall and Cause Vasculitis.

Authors:  Ryu Watanabe; Toshihisa Maeda; Hui Zhang; Gerald J Berry; Markus Zeisbrich; Robert Brockett; Andrew E Greenstein; Lu Tian; Jörg J Goronzy; Cornelia M Weyand
Journal:  Circ Res       Date:  2018-08-31       Impact factor: 17.367

3.  Endovascular Therapy for Intracranial Giant Cell Arteritis : Systematic Review, Technical Considerations and the Effect of Intra-arterial Calcium Channel Blockers.

Authors:  M Travis Caton; Ian T Mark; Kazim H Narsinh; Amanda Baker; Daniel L Cooke; Steven W Hetts; Christopher F Dowd; Van V Halbach; Randall T Higashida; Nerissa U Ko; Sharon A Chung; Matthew R Amans
Journal:  Clin Neuroradiol       Date:  2022-05-03       Impact factor: 3.649

Review 4.  Neurologic manifestations of giant cell arteritis.

Authors:  Antoine Soulages; Igor Sibon; Jean-Michel Vallat; Emmanuel Ellie; Frédéric Bourdain; Fanny Duval; Louis Carla; Marie-Laure Martin-Négrier; Guilhem Solé; Charles Laurent; Agnès Monnier; Gwendal Le Masson; Stéphane Mathis
Journal:  J Neurol       Date:  2022-02-06       Impact factor: 4.849

5.  Incidence of giant cell arteritis in six districts of Paris, France (2015-2017).

Authors:  Solange Gonzalez Chiappe; Sarah Lechtman; Carla Soledad Maldini; Arsène Mekinian; Thomas Papo; Thomas Sené; Alfred Daniel Mahr
Journal:  Rheumatol Int       Date:  2022-07-12       Impact factor: 3.580

6.  Magnetic resonance imaging-based diagnosis of aortitis preceding development of a thoracic aneurysm in a patient with giant cell arteritis: a case report.

Authors:  Georg Lutter; Thomas Puehler; Christoph Röcken; Marcus Both
Journal:  Eur Heart J Case Rep       Date:  2022-04-12

Review 7.  Unmet Needs in the Pathogenesis and Treatment of Vasculitides.

Authors:  Francesco Muratore; Giulia Pazzola; Alessandra Soriano; Nicolò Pipitone; Stefania Croci; Martina Bonacini; Luigi Boiardi; Carlo Salvarani
Journal:  Clin Rev Allergy Immunol       Date:  2018-04       Impact factor: 8.667

Review 8.  Mechanism and biomarkers in aortitis--a review.

Authors:  Benjamin Benhuri; Ammar ELJack; Bashar Kahaleh; Ritu Chakravarti
Journal:  J Mol Med (Berl)       Date:  2019-10-30       Impact factor: 4.599

Review 9.  Neuro-Ophthalmic Emergencies.

Authors:  Samuel J Spiegel; Heather E Moss
Journal:  Neurol Clin       Date:  2021-03-31       Impact factor: 3.806

10.  FLASH: A Novel Tool to Identify Vision-Threating Eye Emergencies.

Authors:  Neil Jairath; Patrick Commiskey; Ariane Kaplan; Yannis M Paulus
Journal:  Int J Ophthalmic Res       Date:  2020-10-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.